MiNK Therapeutics, Inc. announced the appointment of Terese C. Hammond, MD, as Head of Inflammatory and Pulmonary Diseases, effective September 18, 2025. Dr. Hammond is a nationally recognized leader in pulmonary and critical care medicine with extensive experience in advancing registration-stage programs.
Dr. Hammond has served as a principal investigator on multiple pivotal studies and is the lead author of MiNK’s Nature Communications publication on agenT-797 in acute respiratory distress syndrome (ARDS). CEO Jennifer S. Buell, PhD, stated that Dr. Hammond's leadership has advanced MiNK’s iNKT platform in pulmonary diseases.
In her new role, Dr. Hammond will lead the company’s inflammatory and pulmonary disease portfolio, including the imminent grant-supported clinical trial in GvHD and the planned late-stage trial in severe pulmonary disease. These programs are identified as MiNK’s highest priorities, supported by strong biologic rationale and peer-reviewed data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.